We are live on ! Find out more
ADAP

Adaptimmune Therapeutics

Delisted

ADAP was delisted on the 27th of October, 2025.

76 hedge funds and large institutions have $150M invested in Adaptimmune Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

277% more call options, than puts

Call options by funds: $132K | Put options by funds: $35K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 80 → 76 (-4)

5.45% less ownership

Funds ownership: 65.67% → 60.22% (-5.5%)

19% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 21

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

73% less capital inflows, than outflows

Capital inflows: $3.59M | Capital outflows: $13.3M

Holders
76
Holders Change
-4
Holders Change %
-5%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
17
Reduced
21
Closed
11
Calls
$132​K
Puts
$35​K
Net Calls
+$97​K
Net Calls Change
-⁠$158​K

ADAP Hedge Fund Activity: Q2 2024 in Review

76 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2024, worth a combined $150M — down 41% from $256M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADAP and 7 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 17 added.

The largest buyer was Long Focus Capital Management, adding an estimated $1.82M. The largest seller was Baker Bros. Advisors, cutting an estimated $9.27M.

  • 76 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2024, down from 80 in Q1 2024.
  • Funds reported $150M of Adaptimmune Therapeutics stock for Q2 2024, down 41% quarter-over-quarter.
  • 7 funds opened new Adaptimmune Therapeutics positions in Q2 2024 and 11 closed out, a net change of -4 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2024 was Long Focus Capital Management, an estimated $1.82M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2024 was Baker Bros. Advisors, an estimated $9.27M sold.

Based on aggregated 13F filings for Q2 2024.